Supplemental Table 1. Subject disposition.

Number of subjects	Cohort A Total daily dose 5 mg		Cohort B Total daily dose 15 mg		Cohort C Total daily dose 5 mg	
	Ertugliflozin 2.5 mg BID	Ertugliflozin 5 mg QD	Ertugliflozin 7.5 mg BID	Ertugliflozin 15 mg QD	Ertugliflozin 2.5 mg BID	Ertugliflozin 5 mg QD
Assigned to study medication	70					
Treated	20	20	27	28	22	22
Completed	20	20	27	27	20	22
Discontinued	0	0	0	1	2	0
Protocol violation	0	0	0	1	0	0
No longer willing to participate in study	0	0	0	0	1	0
Adverse events	0	0	0	0	1	0
Analyzed for PK						
PK concentration	20	20	27	28	21[a]	22
PK parameter	0	0	27	28	21[a]	22
Analyzed for PD						
PD	0	0	27	28	21[a]	22
Analyzed for safety						
Adverse events	20	20	27	28	22	22
Laboratory data	20	20	27	28	22	22

BID = twice daily; PD = pharmacodynamics; PK = pharmacokinetics; QD = once daily.

Discontinuations were attributed to the last study medication received.

[a]One subject discontinued on day 2 in period 2 (ertugliflozin 2.5 mg BID), and consequently had no PK data for period 2.